{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T15:58:11Z","timestamp":1786723091950,"version":"build-2736575974"},"reference-count":139,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.ymgme.2012.08.003","type":"journal-article","created":{"date-parts":[[2012,8,11]],"date-time":"2012-08-11T12:13:13Z","timestamp":1344687193000},"page":"267-275","source":"Crossref","is-referenced-by-count":87,"title":["Enzyme replacement therapy in patients with Fabry disease: State of the art and review of the literature"],"prefix":"10.1016","volume":"107","author":[{"given":"Antonio","family":"Pisani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Visciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciana Diez","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Sabbatini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Porto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Parenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Imbriaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ymgme.2012.08.003_bb0005","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0010","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-146-6-200703200-00007","article-title":"Narrative review: Fabry disease","volume":"146","author":"Clarke","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0015","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry's disease","volume":"372","author":"Zarate","year":"2008","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ymgme.2012.08.003_bb0020","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"issue":"6","key":"10.1016\/j.ymgme.2012.08.003_bb0025","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/GIM.0b013e3181a23bec","article-title":"A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease","volume":"11","author":"Whybra","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0030","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1542\/peds.2004-1678","article-title":"Pediatric Fabry disease","volume":"115","author":"Ries","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2012.08.003_bb0035","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00431-003-1299-3","article-title":"The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents","volume":"162","author":"Ries","year":"2003","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0040","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/08035250500275022","article-title":"Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey","volume":"95","author":"Ramaswami","year":"2006","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0045","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0050","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1523-1755.2002.00097.x","article-title":"Patients with Fabry disease on dialysis in the United States","volume":"61","author":"Thadhani","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0055","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0060","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","article-title":"Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy","volume":"23","author":"Ortiz","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0065","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ndt\/gfp554","article-title":"End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry","volume":"25","author":"Ortiz","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0070","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","article-title":"Onset and progression of the Anderson-Fabry disease related cardiomyopathy","volume":"130","author":"Kampmann","year":"2008","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0075","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","article-title":"Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events. Natural history data from the Fabry registry","volume":"40","author":"Sims","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.ymgme.2012.08.003_bb0080","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","article-title":"Natural course of Fabry disease: changing pattern of causes of death in FOS\u2014Fabry Outcome Survey","volume":"46","author":"Mehta","year":"2009","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0085","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0090","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1023\/A:1015511908710","article-title":"Quality of life of patients with Fabry disease","volume":"11","author":"Gold","year":"2002","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0095","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1023\/A:1015009210639","article-title":"Assessment of health-related quality-of-life in males with Anderson Fabry disease before therapeutic intervention","volume":"11","author":"Miners","year":"2002","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0100","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/01.gim.0000223545.63012.5a","article-title":"Comparison of health-related quality of life between heterozygous women with Fabry disease, a healthy control population, and patients with other chronic disease","volume":"8","author":"Street","year":"2006","journal-title":"Genet. Med."},{"issue":"3","key":"10.1016\/j.ymgme.2012.08.003_bb0105","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/jmg.2004.025791","article-title":"Effects of enzyme replacement teraphy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey)","volume":"42","author":"Hoffman","year":"2005","journal-title":"J Med Genet."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0110","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","article-title":"Fabry Registry: Nephropathy in males and females with Fabry disease: Cross-sectional description of patients before treatment with enzyme replacement therapy","volume":"23","author":"Ortiz","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: A randomised, doubleblind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.ymgme.2012.08.003_bb0125","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/hrt.2008.162800","article-title":"Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: A prospective long-term cardiac magnetic resonance imaging study","volume":"95","author":"Imbriaco","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.ymgme.2012.08.003_bb0130","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","article-title":"FOS Investigators: Natural course of Fabry disease: Changing pattern of causes of death in FOS \u2013 Fabry Outcome Survey","volume":"46","author":"Mehta","year":"2009","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0135","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0140","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Longterm therapy with agalsidase alfa for Fabry disease: Safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0145","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase alfa and kidney dysfunction in Fabry disease","volume":"20","author":"West","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0150","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0155","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/ncpneph0806","article-title":"Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults","volume":"4","author":"Ortiz","year":"2008","journal-title":"Nat. Clin. Pract. Nephrol."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0160","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1399-0004.2011.01671.x","article-title":"Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey","volume":"81","author":"Ramaswami","year":"2012","journal-title":"Clin. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2012.08.003_bb0170","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/345309","article-title":"Recombinant enzyme therapy for Fabry disease: Absence of editing of human alfa-galactosidase A mRNA","volume":"72","author":"Blom","year":"2003","journal-title":"Am. J. Hum. Genet."},{"issue":"3","key":"10.1016\/j.ymgme.2012.08.003_bb0175","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10038-005-0342-9","article-title":"Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice","volume":"51","author":"Sakuraba","year":"2006","journal-title":"J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.ymgme.2012.08.003_bb0180","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","article-title":"A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease","volume":"13","author":"Lee","year":"2003","journal-title":"Glycobiology"},{"issue":"2","key":"10.1016\/j.ymgme.2012.08.003_bb0185","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: A randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2012.08.003_bb0190","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alfa-galactosidase A \u2013 replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0195","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of _-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease","volume":"97","author":"Schiffmann","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0205","author":"European Medicines Agency"},{"key":"10.1016\/j.ymgme.2012.08.003_bb0210","author":"European Medicines Agency"},{"key":"10.1016\/j.ymgme.2012.08.003_bb0215","unstructured":"European Medicines Agency. Fabrazyme: procedural steps taken and scientific information after the authorisation. Available at: http:\/\/www.ema.europa.eu\/humandocs\/PDFs\/EPAR\/fabrazyme\/101201en8b.pdf. Accessed September 30, 2009."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0220","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ymgme.2012.08.003_bb0225","first-page":"CD006663","article-title":"Enzyme replacement therapy for Anderson-Fabry disease","volume":"12","author":"El Dib","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"11","key":"10.1016\/j.ymgme.2012.08.003_bb0230","doi-asserted-by":"crossref","first-page":"E251","DOI":"10.1503\/cmaj.109-3071","article-title":"Clinical trial for Fabry disease faces continuing hurdles","volume":"181","author":"Silversides","year":"2009","journal-title":"CMAJ."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0235","author":"European Medicines Agency"},{"issue":"2","key":"10.1016\/j.ymgme.2012.08.003_bb0240","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2215\/CJN.06900909","article-title":"Enzyme replacement therapy and Fabry nephropathy","volume":"5","author":"Warnock","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.ymgme.2012.08.003_bb0245","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: Influence of alfa-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine"},{"key":"10.1016\/j.ymgme.2012.08.003_bb0250","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria","volume":"51","author":"Tondel","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0255","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmg.2005.036327","article-title":"Natural history of fabry disease in females in the Fabry Outcome Survey","volume":"43","author":"Deegan","year":"2006","journal-title":"J Med Genet"},{"issue":"5","key":"10.1016\/j.ymgme.2012.08.003_bb0260","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000168482","article-title":"Agalsidase alfa slows the decline in renal function in patients with Fabry disease","volume":"29","author":"Feriozzi","year":"2009","journal-title":"Am. J. Nephrol."},{"issue":"9706","key":"10.1016\/j.ymgme.2012.08.003_bb0265","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: An analysis of registry data","volume":"374","author":"Mehta","year":"2009","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ymgme.2012.08.003_bb0270","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","article-title":"Fabry disease: Overall effects of agalsidase alfa treatment","volume":"34","author":"Beck","year":"2004","journal-title":"Eur. J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.ymgme.2012.08.003_bb0275","first-page":"77","article-title":"Enzyme replacement therapy and renal function in 201 patients with Fabry disease","volume":"66","author":"Schwarting","year":"2006","journal-title":"Clin. Nephrol."},{"issue":"4","key":"10.1016\/j.ymgme.2012.08.003_bb0280","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1432-2277.2008.00824.x","article-title":"Kidney transplantation in patients with Fabry disease","volume":"22","author":"Cybulla","year":"2009","journal-title":"Transpl. Int."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0285","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2215\/CJN.03130411","article-title":"The Effectiveness of Long-Term Agalsidase Alfa Therapy in the Treatment of Fabry Nephropathy","volume":"7","author":"Feriozzi","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.ymgme.2012.08.003_bb0290","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am. J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.ymgme.2012.08.003_bb0295","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10545-005-0575-y","article-title":"Enzyme replacement therapy in Japanese Fabry disease patients: The results of a phase 2 bridging study","volume":"28","author":"Eto","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"issue":"7","key":"10.1016\/j.ymgme.2012.08.003_bb0300","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.ki.5000208","article-title":"Clinical benefit of enzyme replacement therapy in Fabry disease","volume":"69","author":"Breunig","year":"2006","journal-title":"Kidney Int."},{"issue":"21","key":"10.1016\/j.ymgme.2012.08.003_bb0305","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1001\/jama.284.21.2771","article-title":"Clinical features of and recent advances in therapy for Fabry disease","volume":"284","author":"Brady","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2012.08.003_bb0310","article-title":"A-galactosidase deficiency: Fabry disease","volume":"3","author":"Desnick","year":"2001"},{"issue":"5","key":"10.1016\/j.ymgme.2012.08.003_bb0320","first-page":"469","article-title":"Cardiac variant of Fabry's disease mimicking hypertrophic cardiomyopathy","volume":"44","author":"Chimenti","year":"1999","journal-title":"Cardiologia"},{"key":"10.1016\/j.ymgme.2012.08.003_bb0325","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/hrt.2005.063818","article-title":"The heart in Anderson-Fabry disease and other lysosomal storage disorders","volume":"93","author":"Linhart","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.ymgme.2012.08.003_bb0330","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2012.08.003_bb0335","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1371\/journal.pone.0000598","article-title":"Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg\/kg","volume":"28","author":"Vedder","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2012.08.003_bb0340","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s10545-006-0361-5","article-title":"Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease","volume":"29","author":"Bierer","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0345","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.ajkd.2005.03.016","article-title":"Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement","volume":"46","author":"Pisani","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0350","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10545-006-0221-3","article-title":"The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease","volume":"29","author":"Kalliokoski","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"issue":"11","key":"10.1016\/j.ymgme.2012.08.003_bb0355","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1055\/s-0031-1281744","article-title":"Right ventricular involment in patients with Fabry's disease and the effect of enzyme replacement therapy","volume":"183","author":"Wuest","year":"2011","journal-title":"Rofo"},{"key":"10.1016\/j.ymgme.2012.08.003_bb0360","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s10545-008-0848-3","article-title":"Twenty-fourmonth alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters","volume":"31","author":"Koskenvuo","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2012.08.003_bb0365","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1651-2227.2008.00700.x","article-title":"Cardiac manifestation of Anderson-Fabry disease in children and adolescent","volume":"97","author":"Kampmann","year":"2008","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0370","first-page":"39","article-title":"Enzyme replacement therapy in Anderson-Fabry cardiomyopathy","volume":"18","author":"Kampmann","year":"2002","journal-title":"Heart Metab."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0375","series-title":"Fabry Disease: Perspectives from Five Years of FOS","article-title":"Enzyme replacement therapy and the heart","author":"Kampmann","year":"2006"},{"issue":"9","key":"10.1016\/j.ymgme.2012.08.003_bb0380","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.clinthera.2009.09.008","article-title":"Effect of agalsidase alfa replacement therapy on Fabry disease- related hypertrophic cardiomyopathy: A 12- to 36-month, retrospective, blinded echocardiographic pooled analysis","volume":"31","author":"Kampmann","year":"2009","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0385","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/hrt.2004.054015","article-title":"Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with a\u00b4 galactosidase A","volume":"92","author":"Elliott","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.ymgme.2012.08.003_bb0390","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.amjcard.2005.11.087","article-title":"Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy","volume":"97","author":"Beer","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0395","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2012.08.003_bb0400","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1399-0004.2004.00284.x","article-title":"Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease","volume":"66","author":"Spinelli","year":"2004","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0405","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2009.01.003","article-title":"Fabry disease","volume":"122","author":"Schiffmann","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0410","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.10497","article-title":"Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease","volume":"28","author":"Schiffmann","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2012.08.003_bb0415","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1161\/hc3801.096352","article-title":"Regional cerebral hyperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy","volume":"104","author":"Moore","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2012.08.003_bb0420","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2377-2-4","article-title":"Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease","volume":"2","author":"Moore","year":"2002","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0425","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/hs0202.102601","article-title":"Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement","volume":"33","author":"Moore","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.ymgme.2012.08.003_bb0430","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1023\/B:BOLI.0000028794.04349.91","article-title":"CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy","volume":"27","author":"Jardim","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0435","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1590\/S0004-282X2006000500002","article-title":"White matter lesions in Fabry disease before and after enzyme replacement therapy: a 2-year follow-up","volume":"64","author":"Jardim","year":"2006","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0440","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1023\/B:BOLI.0000009948.86528.72","article-title":"Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy","volume":"26","author":"Hajioff","year":"2003","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0445","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s00415-007-0575-y","article-title":"Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy","volume":"254","author":"Palla","year":"2007","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0450","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","article-title":"Enzyme replacement therapy improves function of C-, Aa\u00a8-, and Aa\u02c6-nerve fibers in Fabry neuropathy","volume":"62","author":"Hilz","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2012.08.003_bb0455","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1023\/B:BOLI.0000005658.14563.77","article-title":"Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study","volume":"26","author":"Baehner","year":"2003","journal-title":"J. Inherit. Metab. Dis."},{"issue":"11","key":"10.1016\/j.ymgme.2012.08.003_bb0460","doi-asserted-by":"crossref","first-page":"03","DOI":"10.1097\/GIM.0b013e3181f13a4a","article-title":"Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry","volume":"12","author":"Watt","year":"2010","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0465","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","article-title":"Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry","volume":"30","author":"Eng","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0470","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1023\/B:BOLI.0000037342.59612.69","article-title":"Relief of gastrointestinal symptoms under enzyme replacement therapy in patients with Fabry disease","volume":"27","author":"Dehout","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0475","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","article-title":"Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, openlabel study in pediatric patients with Fabry disease","volume":"152","author":"Wraith","year":"2008","journal-title":"J. Pediatr."},{"issue":"11","key":"10.1016\/j.ymgme.2012.08.003_bb0480","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1210\/jc.2006-0858","article-title":"Endocrine dysfunction in patients with Fabry disease","volume":"91","author":"Faggiano","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0485","first-page":"1","article-title":"Thyroid function in Fabry disease before and after enzyme replacement therapy","volume":"36","author":"Faggiano","year":"2011","journal-title":"Minerva Endocrinol."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0490","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1523-1755.2002.00097.x","article-title":"Patients with Fabry disease on dialysis in the United States","volume":"61","author":"Thadhani","year":"2002","journal-title":"Kidney Int."},{"issue":"Suppl. 7","key":"10.1016\/j.ymgme.2012.08.003_bb0495","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/ndt\/11.supp7.4","article-title":"Report on management of renale failure in Europe, XXVI,: Rare diseases in renal replacement therapy in the ERA-EDTA Registry","volume":"11","author":"Tsakiris","year":"1996","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0500","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1097\/00007890-200006150-00020","article-title":"Excellent outcome of renal transplantation in patients with Fabry's disease","volume":"69","author":"Ojo","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.ymgme.2012.08.003_bb0505","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/TP.0b013e318191a842","article-title":"Kidney transplant outcomes in patients with Fabry disease","volume":"87","author":"Shah","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.ymgme.2012.08.003_bb0510","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2215\/CJN.05570809","article-title":"Dialysis and Transplantation in Fabry Disease: Indications for Enzyme Replacement Therapy","volume":"5","author":"Mignani","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0515","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/ndt\/gfm096","article-title":"Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease","volume":"22","author":"Pastores","year":"2007","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0520","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1523-1755.2004.00883.x","article-title":"Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease","volume":"66","author":"Kosch","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0525","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/ndt\/gfm813","article-title":"Agalsidase therapy in patients with Fabry disease on renal replacement therapy: A nationwide study in Italy","volume":"23","author":"Mignani","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0530","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1523-1755.2004.00514.x","article-title":"Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: A pilot study","volume":"65","author":"Mignani","year":"2004","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.ymgme.2012.08.003_bb0535","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1742-1241.2006.01237.x","article-title":"Clinical results of enzyme replacement therapy in Fabry disease: A comprehensive review of literature","volume":"61","author":"Lidove","year":"2007","journal-title":"Int. J. Clin. Pract."},{"issue":"4","key":"10.1016\/j.ymgme.2012.08.003_bb0540","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ymgme.2009.11.001","article-title":"Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative","volume":"99","author":"Sirrs","year":"2009","journal-title":"Mol. Genet. Metab."},{"issue":"9354","key":"10.1016\/j.ymgme.2012.08.003_bb0545","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0140-6736(03)12357-4","article-title":"Enzyme replacement in Anderson-Fabry disease","volume":"361","author":"Bengtsson","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ymgme.2012.08.003_bb0550","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/01.GIM.0000069509.57929.CD","article-title":"Comparative evaluation of alfagalactosidase A infusions for treatment of Fabry disease","volume":"5","author":"Hopkin","year":"2003","journal-title":"Genet. Med."},{"issue":"7","key":"10.1016\/j.ymgme.2012.08.003_bb0555","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/14712598.4.7.1167","article-title":"Enzyme replacement therapy for Fabry disease: Lessons from two alfa-galactosidase A orphan products and one FDA approval","volume":"4","author":"Desnick","year":"2004","journal-title":"Expert Opin. Biol. Ther."},{"issue":"3","key":"10.1016\/j.ymgme.2012.08.003_bb0560","first-page":"354","article-title":"Enzyme replacement therapy in Fabry's disease: Recent advances and clinical applications","volume":"17","author":"Mignani","year":"2004","journal-title":"J. Nephrol."},{"issue":"3","key":"10.1016\/j.ymgme.2012.08.003_bb0565","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","article-title":"Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3","volume":"94","author":"Vedder","year":"2008","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2012.08.003_bb0570","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","article-title":"Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy","volume":"1812","author":"Van Breemen","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2012.08.003_bb0575","first-page":"S51","article-title":"The Canadian Fabry Disease Initiative: A randomised controlled trial of agalsidase therapy in Fabryneuropathy","volume":"48","author":"West","year":"2010","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"S39","key":"10.1016\/j.ymgme.2012.08.003_bb0580","article-title":"A randomised controlled trial of enzyme replacement therapy in Fabry disease: The Canadian disease initiative at year three","volume":"99","author":"West","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0585","doi-asserted-by":"crossref","DOI":"10.1038\/gim.2012.39","article-title":"Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)","author":"Tsuboi","year":"2012","journal-title":"Genet. Med."},{"issue":"Suppl. 2","key":"10.1016\/j.ymgme.2012.08.003_bb0590","article-title":"Effects of switch therapy with agalsidase-alfa in patients with anderson-fabry disease (afd)previously treated with agalsidase-beta: a prospective cardiac magnetic resonance imaging study","volume":"27","author":"Russo","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0720","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic indicators of renal disease progression in adults with Fabry disease: Natural history data from the Fabry Registry","volume":"5","author":"Wanner","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0600","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1681\/ASN.2006111263","article-title":"Ries M:Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing","volume":"18","author":"Schiffmann","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0605","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3109\/08860220903150296","article-title":"Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: A Brazilian experience","volume":"31","author":"Thofehrn","year":"2009","journal-title":"Ren. Fail."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0610","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1681\/ASN.2006121400","article-title":"Antiproteinuric therapy and Fabry nephropathy: Sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta","volume":"18","author":"Tahir","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0615","doi-asserted-by":"crossref","first-page":"c43","DOI":"10.1159\/000320903","article-title":"Blood pressure, proteinuria and nephropathy in Fabry disease","volume":"118","author":"Jain","year":"2011","journal-title":"Nephron Clin. Pract."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0620","article-title":"Renal outcome of agalsidase beta treatment for Fabry disease: Role of proteinuria and timing of treatment initiation","author":"Warnock","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0625","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/sj.ki.5001794","article-title":"Predicting initiation and progression of chronic kidney disease: Developing renal risk scores","volume":"70","author":"Taal","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0630","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-136-8-200204160-00010","article-title":"Chronic renal diseases: Renoprotective benefits of renin-angiotensin system inhibition","volume":"136","author":"Remuzzi","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0635","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1097\/01.ASN.0000100145.27188.33","article-title":"Management of glomerular proteinuria: A commentary","volume":"14","author":"Wilmer","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2012.08.003_bb0640","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1681\/ASN.2004110968","article-title":"Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: The data of the meta-analyses","volume":"16","author":"Chiurchiu","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0645","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00109-010-0686-2","article-title":"ACE activity is modulated by the enzyme a-galactosidase A","volume":"89","author":"Batista","year":"2011","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.ymgme.2012.08.003_bb0650","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1212\/WNL.23.8.871","article-title":"Relief of pain of Fabry's disease by diphenylhydantoin","volume":"23","author":"Lockman","year":"1973","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2012.08.003_bb0655","first-page":"704","article-title":"Fabry's disease Carbamazepine therapy in acrodyniform syndrome","volume":"34","author":"Lenoir","year":"1977","journal-title":"Arch. Fr. Pediatr."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0660","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1051\/jbio\/2002196020183","article-title":"Fabry's disease (alpha-galactosidase-A deficiency): recent therapeutic innovations","volume":"196","author":"Germain","year":"2002","journal-title":"J. Soc. Biol."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0665","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/00006231-199809000-00009","article-title":"Gastrointestinal symptoms and delayed gastric emptying in Fabry's disease: response to metoclopramide","volume":"19","author":"Argoff","year":"1998","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0670","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/00128071-200304030-00005","article-title":"Fabry disease: recognition and management of cutaneous manifestations","volume":"4","author":"Mohrenschlager","year":"2003","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0675","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ymthe.2006.01.006","article-title":"Gene therapy for lysosomal storage diseases","volume":"13","author":"Sands","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0680","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrd708","article-title":"Targeting glycosylation as a therapeutic approach","volume":"1","author":"Dwek","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0685","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2012.08.003_bb0690","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:BOLI.0000045756.54006.17","article-title":"Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease","volume":"27","author":"Elstein","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0695","doi-asserted-by":"crossref","first-page":"8229","DOI":"10.1074\/jbc.M708735200","article-title":"Niemann-Pick type C1 I1061T mutant encodes a functional protein that is selected for endoplasmic reticulum-associated degradation due to protein misfolding","volume":"283","author":"Gelsthorpe","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0700","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbrc.2008.02.125","article-title":"Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase","volume":"369","author":"Shen","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0705","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/mt.2009.53","article-title":"The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts","volume":"17","author":"Porto","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2012.08.003_bb0710","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1111\/j.1742-4658.2007.06041.x","article-title":"Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors","volume":"274","author":"Fan","year":"2007","journal-title":"FEBS J."},{"issue":"3","key":"10.1016\/j.ymgme.2012.08.003_bb0715","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10545-011-9424-3","article-title":"Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease","volume":"35","author":"Porto","year":"2012","journal-title":"J. Inherit. Metab. Dis."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719212003034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719212003034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T15:38:24Z","timestamp":1562081904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719212003034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":139,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S1096719212003034"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2012.08.003","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}